AzTrials
AzTrials

Esophageal AchalasiaPhase 3NCT07425977

Transverse vs Longitudinal Mucosal Incision During POEM

A Phase 3 study testing Transverse Mucosal Incision During POEM and Longitudinal Mucosal Incision During POEM in people with Esophageal Achalasia and Spastic Esophageal Motility Disorders, run by Universidad Nacional de Colombia at 1 site in Colombia.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Peroral endoscopic myotomy (POEM) is a minimally invasive endoscopic procedure used to treat achalasia and other spastic esophageal motility disorders. A key step in POEM is creating a small opening in the esophageal lining (mucosal incision) to enter the submucosal tunnel. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Transverse Mucosal Incision During POEM and Longitudinal Mucosal Incision During POEM
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
140 participants
Where
1 siteColombia
Study dates
22 Feb 2026to 2 Aug 2026
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18 years
  • Diagnosis of achalasia or other spastic esophageal motility disorders with an indication for POEM
  • ASA physical status I-III
  • Ability to provide informed consent

Who cannot join

  • Prior myotomy or major esophageal surgery
  • Uncorrectable coagulopathy
  • Pregnancy
  • Active systemic infection
  • Contraindication to anesthesia
  • Any situation predicting technical inability to perform POEM

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Juan P Alzate, MD, MsC contact

+573102587912

jpalzategr@unal.edu.co

Colombia1 site
  • Alzate

    Bogotá

    Juan P Alzate, +573102587912, jpag6@hotmail.com

Other trials in Colombia

About this study

Official title: Transverse Versus Longitudinal Mucosal Incision in Peroral Endoscopic Myotomy: A Multicenter Randomized Clinical Trial

Peroral endoscopic myotomy (POEM) is a minimally invasive endoscopic procedure used to treat achalasia and other spastic esophageal motility disorders. A key step in POEM is creating a small opening in the esophageal lining (mucosal incision) to enter the submucosal tunnel. This study evaluates whether making that entry incision transverse (across the esophagus) versus longitudinal (along the esophagus) improves procedural efficiency without reducing safety.

This is a multicenter, randomized (1:1), parallel-group clinical trial conducted in three therapeutic endoscopy units in Colombia (Hospital Universitario del Valle and Clínica Versalles in Cali, and Clínica del Occidente in Bogotá). Adults (≥18 years) with an indication for POEM, ASA I-III, and ability to provide informed consent will be eligible; key exclusions include prior myotomy/major esophageal surgery, uncorrectable coagulopathy, pregnancy, active systemic infection, anesthesia contraindication, or anticipated technical inability to perform POEM.

Read more

All procedures are standardized: POEM under general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives and preset electrosurgical modes; hemostasis with Coagrasper® only if needed; and closure using standard through-the-scope (TTS) clips. Participants are randomly assigned to a 15 mm transverse mucosal incision (perpendicular to the esophageal axis) or a 15 mm longitudinal mucosal incision. Full-procedure video is recorded for quality control and to allow objective timing, with blinded assessment of the primary outcome.

The primary outcome is the time (seconds) from the first mucosal cut to successful entry of the endoscope cap into the submucosal tunnel (advancing at least 1 cm). Secondary outcomes include need for hemostasis with Coagrasper®, number of clips required for complete closure, and early complications (including perforation and gas-related events such as capnoperitoneum requiring decompression and emphysema), monitored through 30 days.

Participants complete a screening/preoperative visit (up to 30 days before), undergo the POEM procedure, have early in-hospital/discharge assessment (days 1-2), and receive safety follow-up contacts at approximately 1 week and day 30.

Risks are those expected from standard POEM and peri-anesthesia care (e.g., bleeding, perforation, infection, and gas-related complications), and participants may not directly benefit clinically. However, the transverse incision may shorten access and closure time and reduce resource use without increasing short-term complications.

The study will be conducted with written informed consent, confidentiality protections (pseudonymization and secure storage), and reporting of results in aggregate form.

Being tested
Transverse Mucosal Incision During POEM, Longitudinal Mucosal Incision During POEM
Medical subject headings
Esophageal Achalasia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transverse Mucosal Incision During POEMProcedure or surgery

    POEM performed with a 15 mm transverse mucosal incision (perpendicular to the esophageal axis) for entry into the submucosal tunnel, under a standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded).

  • Longitudinal Mucosal Incision During POEMProcedure or surgery

    POEM performed with a 15 mm longitudinal mucosal incision (parallel to the esophageal axis) for entry into the submucosal tunnel, under the same standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded).

Study groups in NCT07425977
Study groupRoleWhat they receive
Transverse Mucosal Incision During POEMExperimentalPOEM performed with a 15 mm transverse mucosal incision (perpendicular to the esophageal axis) for entry into the submucosal tunnel, under a standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded)
Receives: Procedure: Transverse Mucosal Incision During POEM
Longitudinal Mucosal Incision During POEMActive comparatorPOEM performed with a 15 mm longitudinal mucosal incision (parallel to the esophageal axis) for entry into the submucosal tunnel, under the same standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded)
Receives: Procedure: Longitudinal Mucosal Incision During POEM

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to Effective Submucosal Tunnel Entry (Seconds)

    Time (in seconds) from the first mucosal cut to effective entry of the endoscope cap into the submucosal tunnel, defined as allowing advancement of at least 1 cm.

    Measured: During the POEM procedure (Day 0; intraoperative)

Secondary outcomes (2)
  1. Bleeding Requiring Hemostasis With Coagrasper®

    Proportion of procedures with bleeding that requires hemostasis using Coagrasper® (Yes/No).

    Measured: During the POEM procedure (Day 0; intraoperative)

  2. Procedure-Related Complications (Up to 30 Days)

    Any complication related to the procedure, monitored through 30 days.

    Measured: Up to 30 days after the procedure (contacts at ~1 week and Day 30; plus early assessment Days 1-2).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Feb 2026
  2. Study start22 Feb 2026 (estimated)
  3. Primary completion2 Jul 2026 (estimated)
  4. Study completion2 Aug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
140 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07425977
Sponsor's protocol ID
DE-F-254-V8
Status last verified
Feb 2026
First submitted
16 Feb 2026
Last updated
24 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Transverse Mucosal Incision During POEM and Longitudinal Mucosal Incision During POEM in people with Esophageal Achalasia and Spastic Esophageal Motility Disorders, run by Universidad Nacional de Colombia at 1 site in Colombia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 24 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Colombia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Juan P Alzate, MD, MsC (+573102587912, jpalzategr@unal.edu.co), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to Effective Submucosal Tunnel Entry (Seconds) (time frame: During the POEM procedure (Day 0; intraoperative)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in